Recurrent vulvovaginal candidiasis.
Sobel JD.
Am J Obstet Gynecol. 2016 Jan;214(1):15-21. doi: 10.1016/j.ajog.2015.06.067. Epub 2015 Jul 9.
Recurrent vulvovaginal candidiasis.
Blostein F, Levin-Sparenberg E, Wagner J, Foxman B.
Ann Epidemiol. 2017 Sep;27(9):575-582.e3. doi: 10.1016/j.annepidem.2017.08.010. Epub 2017 Aug 15.
Recurrent vulvovaginal candidiasis.
Belayneh M, Sehn E, Korownyk C.
Can Fam Physician. 2017 Jun;63(6):455.
Global burden of recurrent vulvovaginal candidiasis: a systematic review.
Denning DW, Kneale M, Sobel JD, Rautemaa-Richardson R.
Lancet Infect Dis. 2018 Nov;18(11):e339-e347. doi: 10.1016/S1473-3099(18)30103-8. Epub 2018 Aug 2.
Recurrent vulvovaginal candidiasis.
Sheary B, Dayan L.
Aust Fam Physician. 2005 Mar;34(3):147-50.
Recurrent vulvovaginal candidiasis.
Lines A, Vardi-Flynn I, Searle C.
BMJ. 2020 Jun 8;369:m1995. doi: 10.1136/bmj.m1995.
Antifungal (oral and vaginal) therapy for recurrent vulvovaginal candidiasis: a systematic review protocol.
Lírio J, Giraldo PC, Amaral RL, Sarmento ACA, Costa APF, Gonçalves AK.
BMJ Open. 2019 May 22;9(5):e027489. doi: 10.1136/bmjopen-2018-027489.
Recurrent vulvovaginal candidiasis: A review of guideline recommendations.
Matheson A, Mazza D.
Aust N Z J Obstet Gynaecol. 2017 Apr;57(2):139-145. doi: 10.1111/ajo.12592. Epub 2017 Mar 15.
Recurrent vulvovaginal candidiasis.
Ringdahl EN.
Mo Med. 2006 Mar-Apr;103(2):165-8.
Phase 3 study evaluating the safety and efficacy of oteseconazole in the treatment of recurrent vulvovaginal candidiasis and acute vulvovaginal candidiasis infections.
Martens MG, Maximos B, Degenhardt T, Person K, Curelop S, Ghannoum M, Flynt A, Brand SR.
Am J Obstet Gynecol. 2022 Dec;227(6):880.e1-880.e11. doi: 10.1016/j.ajog.2022.07.023. Epub 2022 Jul 19.
